Alex Azar was confirmed as the next secretary of Health and Human Services with strong industry support. Azar comes to the role with some homework to do on key FDA medtech policies, but has expressed support for risk-based regulation of lab-developed tests and cost-saving bundled-payment models.
The device industry gave its warm support Jan. 24 to the incoming US secretary of Health and Human Services, Alex Azar, who was confirmed by the Senate Jan. 24 in a 55-43 vote.
Azar is a former drug industry executive at Eli Lilly & Co., and a former HHS official during the George W. Bush administration.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
